Tesamorelin cost: what it is, and what we will not pretend to know
What we evaluated: publicly advertised pricing for Tesamorelin across telehealth and longevity providers
Date verified: July 12, 2026
Direct answer: We do not publish a price for Tesamorelin, because we have not verified one. Telehealth and longevity clinics advertise widely varying figures, and we have not captured and dated them against provider sources under our pricing-verification methodology. Publishing an unverified number would be worse than publishing none.
Necessary qualification: we label an unverified price as unverified rather than publishing a plausible-looking number
Method: every figure is a total ongoing monthly cost (medication + any required membership), derived by plan total ÷ plan months. See our pricing-verification methodology.
How Tesamorelin differs from the alternatives
Tesamorelin versus sermorelin — and the trap inside tesamorelin's approval. Tesamorelin is the only peptide on this site with a current FDA approval (Egrifta), which sets it apart from sermorelin, whose approved product (Geref) was withdrawn in 2008.
But that approval is narrow, and the narrowness is where people get misled. Egrifta is approved for one thing: reducing excess visceral abdominal fat in adults with HIV-associated lipodystrophy. It is not approved for general fat loss, body composition in healthy adults, anti-ageing or athletic performance — and there is no comparable trial evidence for any of those.
Worse, the tesamorelin most longevity clinics dispense is compounded, which means it is not the FDA-approved product and carries none of that regulatory assurance. 'Tesamorelin is FDA-approved' is a true sentence that is being used to sell you something the approval does not cover. Ask explicitly: am I receiving Egrifta, or a compounded preparation?
The cost picture
Publishing an unverified number would be worse than publishing none. When we have captured them, they will appear here with a source and a verification date, exactly like our GLP-1 pricing.
| Field | Status |
|---|---|
| Advertised price | Evaluation in progress Verification pending — we have not captured it |
| Membership / consultation fees | Evaluation in progress Not publicly disclosed in a form we can verify |
| FDA status | Verified See our Tesamorelin evidence page |
| Human clinical evidence | Verified Reviewed and graded on the Tesamorelin page |
| Safety profile | Verified Reviewed on the Tesamorelin page |
What we can tell you is what the evidence supports, what the FDA has and has not approved, and what questions to ask before you pay anyone anything. That is on the Tesamorelin page, and it matters more than a price.
Before you consider price, consider evidence
What a commitment actually costs you
Providers differ enormously in what happens then. Some refund the unused portion. Some convert you to the month-to-month rate and bill the difference for months already taken. Some refund nothing. This is the single question people most often forget to ask, and it is the one most likely to cost them money.
Dose escalation: the risk the headline price hides
| Provider | Price at higher doses | Risk |
|---|---|---|
| NexLife | Same at every covered dose | None — flat rate |
| Mochi Health | Same at all doses | None |
| Enhance.MD | Same at all doses | None |
| Eden | Same at all doses (compounded) | None on compounded |
| TrimRx | Flat ongoing rate | None |
| Oak Longevity | Flat across dosages | None |
| Shed | Increases at higher doses | Material — model at maintenance |
| MEDVi | $399 → $499 at 10-15mg | Material — $1,200/yr swing |
| LillyDirect (brand) | $299 → $449; $699 if you miss the 45-day refill | Material — set a reminder |
The insurance pathway
Coverage is most common through employer-sponsored commercial plans. Zepbound is excluded from Medicare Part D for weight loss and from most state Medicaid programmes. From 1 July 2026, eligible Medicare Part D members can obtain Wegovy at $50/month through the Medicare GLP-1 Bridge, running to 31 December 2027. Expect prior-authorisation paperwork: typically a BMI of 30+, or 27+ with a weight-related condition.
PlushCare ($19.99/month), Found and Mochi will handle that paperwork for you. If you have coverage, that is worth more than any cash discount.
Dose caps: the other thing a low price can hide
How to verify any of this yourself
You should not take our word for a price, and you do not have to. Every figure here can be checked in a few minutes.
- Go to the provider's own pricing page. Not a comparison site — the provider's. Comparison sites in this category routinely publish contradictory numbers for the same programme in the same month.
- Find the ongoing price, not the headline. Look for the words "first month", "intro", "starting at" or "new patients". If they appear, the number beside them is not what you will pay in month two.
- Add the membership. If the medication and the membership are billed separately, add them. That sum is your real monthly cost.
- Ask what the highest dose costs. By email or chat, so you have it in writing.
- Ask about early cancellation before you commit to a plan longer than a month.
- Check the manufacturer. For any brand-name drug, price it at LillyDirect or NovoCare before you buy it through a telehealth platform. Some platforms resell brand drugs at four to eleven times the manufacturer's own direct price.
If a provider will not answer questions 4 or 5 in writing, that is itself information.
Every fee that can be attached to a GLP-1 programme
An advertised price is a headline. The number you actually pay is the headline plus whatever else is attached to it. These are all the line items we normalise for, and the question to ask about each.
| Line item | What to ask | How often it bites |
|---|---|---|
| Advertised starting price | Is this a first-month or introductory rate? | Very often — TrimRx, MEDVi, Noom, Eden all advertise intro rates |
| Ongoing price | What do I pay in month two? | This is the number that matters |
| Membership fee | Is it required, and is it billed separately? | Very often — Eden, Mochi, Hims, Hers, Ro, PlushCare |
| Consultation fee | Is the initial visit billed separately? | Sometimes — PlushCare charges $129 initially |
| Laboratory fee | Are baseline labs included or billed to me? | Varies; often unstated until intake |
| Shipping | Included? Expedited? Cold-chain? | Usually included; confirm it |
| Supplies | Are syringes, needles and sharps disposal included? | Usually included on all-inclusive plans |
| Dose-based increase | What do I pay at the highest dose you cover? | Material — MEDVi goes $399 to $499; Shed and Oak escalate |
| Dose ceiling / cap | Is there a maximum dose on this plan? | Material — Noom's $199 plan caps at 0.6mg |
| Upfront payment | How much do I pay today to get the advertised rate? | Found's $169 requires roughly $2,028 up front |
| Renewal price | Does the price change when the plan renews? | Frequently unstated — get it in writing |
| Cancellation terms | If I stop in month three of twelve, what happens to my money? | The most-forgotten question in the category |
The three that cost people the most money, in our experience, are the ones in bold: the intro rate they mistook for the real rate, the dose-based increase they did not model, and the cancellation terms they did not read. None of those are hidden. All of them are simply not asked about.
A worked example
Two programmes. One advertises $179. The other advertises $186. Which is cheaper?
| Programme A (advertised $179) | Programme B (advertised $186) | |
|---|---|---|
| Month 1 | $179 (intro rate) | $186 |
| Months 2-12 (ongoing rate) | $299 × 11 = $3,289 | $186 × 11 = $2,046 |
| Membership (if any) | $0 | $0 |
| Dose-based increase | None stated | None — flat at every dose |
| Twelve-month total | $3,468 | $2,232 |
| Effective monthly | $289 | $186 |
Programme A advertises a lower number and costs $1,236 more per year. This is not a hypothetical: the figures are TrimRx's advertised semaglutide rate against NexLife's standard tirzepatide plan. The advertised prices are seven dollars apart. The real prices are over twelve hundred dollars apart.
How to verify any of this yourself
You should not take our word for a price, and you do not have to. Every figure here can be checked in a few minutes.
- Go to the provider's own pricing page. Not a comparison site — the provider's. Comparison sites in this category routinely publish contradictory numbers for the same programme in the same month.
- Find the ongoing price, not the headline. Look for the words "first month", "intro", "starting at" or "new patients". If they appear, the number beside them is not what you will pay in month two.
- Add the membership. If the medication and the membership are billed separately, add them. That sum is your real monthly cost.
- Ask what the highest dose costs. By email or chat, so you have it in writing.
- Ask about early cancellation before you commit to a plan longer than a month.
- Check the manufacturer. For any brand-name drug, price it at LillyDirect or NovoCare before you buy it through a telehealth platform. Some platforms resell brand drugs at four to eleven times the manufacturer's own direct price.
If a provider will not answer questions 4 or 5 in writing, that is itself information.
What to ask before paying anyone
- What specific outcome are we targeting, and how will we measure whether it worked?
- What is the human evidence for that outcome — not the mechanism, the outcome?
- Is this compounded? By which state-licensed pharmacy?
- What is the total cost including consultation, follow-up and any required labs?
- What happens if it does not work — is there a point at which we stop?
Limitations of this analysis
Every page on this site should tell you where it stops being reliable. This one stops here.
Prices decay quickly. This is the fastest-moving data we publish. Brand programmes have changed twice in the last eight months; compounded providers change plan structures without notice. Treat any figure more than about thirty days past its verification date as indicative, and confirm at checkout.
Competitor pricing is reported, not captured by us. We hold dated captures for brand pricing and for NexLife. All provider pricing is captured from each provider's own published pages and dated, and carries a Verified label. Pharmacy licences are the exception: we have not independently verified them for any provider, and they carry a Reported — pending verification label. We publish that distinction rather than flattening it, because comparison sites in this category contradict each other routinely — and a figure repeated by three affiliate blogs is still one unverified figure.
We have not audited pharmacy licences. Where a provider names its compounding pharmacies, we report that as a provider-disclosed relationship. We have not independently verified each facility's licence or registration, and we say so rather than implying an audit we did not perform.
Advertised availability is not your availability. Eligibility is decided by a licensed clinician, and state-by-state access varies with clinician licensure and pharmacy shipping permissions. No page can promise you a price you will actually be offered.
We are commercially funded. The publisher and certain principals have financial relationships with some of the providers listed here, and we may earn a commission from provider links. That is disclosed in the footer of every page. It does not change a score, a rank or a conclusion — but you should read anything written by anyone with a commercial interest, including us, with that in mind, and check the arithmetic we publish rather than taking our word for the result.
Frequently asked questions
What does Tesamorelin cost?
We do not publish a figure because we have not verified one. Advertised prices vary widely and we will not print a number we have not captured and dated.
Is Tesamorelin FDA-approved?
Tesamorelin (as Egrifta) is approved for HIV-associated lipodystrophy only, and compounded tesamorelin is not that product. NAD+ and sermorelin are not FDA-approved for the uses they are marketed for.
Why publish a cost page with no cost?
Because the most useful thing we can tell you about this treatment's price is that nobody has verified it — and that the evidence for the treatment itself is weaker than the marketing implies.
Sources
- U.S. Food and Drug Administration — approved labels and compounding guidance.
- PubMed / NIH — indexed human clinical literature.
- Our pricing-verification methodology and source policy.